sorbitol has been researched along with glucagon-like peptide 1 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, R; Byrne, MM; Göke, B; Katschinski, M; Pluntke, K; Schirra, J; Wank, U | 1 |
| Flatt, PR; Lawlor, A; Mooney, MH; O'Harte, FP | 1 |
| Flatt, PR; Gault, VA; Green, BD; O'Harte, FP | 1 |
| Berstad, A; Holst, JJ; Morken, MH; Valeur, J; Øines, E | 1 |
| Gunji, E; Io, F; Kato, K; Kimura, K; Koretsune, H; Okumura-Kitajima, L; Sugisaki-Kitano, M; Uchida, S; Yamamoto, K | 1 |
| Bando, S; Fujimoto, K; Ichikawa, R; Miyatsuka, T; Motomiya, T; Shichiri, M; Taguchi, M; Taguchi, T; Takano, K | 1 |
1 trial(s) available for sorbitol and glucagon-like peptide 1
| Article | Year |
|---|---|
Inhibitory effects of hyperglycaemia on fed jejunal motility: potential role of hyperinsulinaemia.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Drug Combinations; Gastrointestinal Motility; Gastrointestinal Transit; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Hyperglycemia; Hyperinsulinism; Insulin; Jejunum; Male; Pancreatic Polypeptide; Peptide Fragments; Perfusion; Phospholipids; Protein Precursors; Sorbitol | 1998 |
5 other study(ies) available for sorbitol and glucagon-like peptide 1
| Article | Year |
|---|---|
N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo.
Topics: Animals; Blood Glucose; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Male; Peptide Fragments; Peptides; Rats; Rats, Wistar; Sorbitol | 2000 |
A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Topics: Animals; Blood Glucose; Cell Culture Techniques; Cell Line; Cyclic AMP; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Mice; Mice, Obese; Sorbitol; Spectrometry, Mass, Electrospray Ionization | 2005 |
Plasma glucagon-like peptide 1 and peptide YY levels are not altered in symptomatic fructose-sorbitol malabsorption.
Topics: Adult; Breath Tests; Case-Control Studies; Female; Food Hypersensitivity; Fructose; Glucagon-Like Peptide 1; Humans; Malabsorption Syndromes; Male; Middle Aged; Peptide YY; Sorbitol | 2008 |
SGL5213, a novel and potent intestinal SGLT1 inhibitor, suppresses intestinal glucose absorption and enhances plasma GLP-1 and GLP-2 secretion in rats.
Topics: Animals; Diabetes Mellitus, Experimental; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucose; Intestinal Absorption; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 1; Sorbitol | 2019 |
Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Sorbitol | 2022 |